Imunon, Inc. Amortization of Debt Issuance Costs
Imunon, Inc. (IMNN) reported Amortization of Debt Issuance Costs of $6.98 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AmortizationOfFinancingCosts · last filed 2026-08-11
- Imunon, Inc. amortization of debt issuance costs for the quarter ending 2013-09-30 was $35.70K.
- Imunon, Inc. amortization of debt issuance costs for the quarter ending 2013-06-30 was $31.56K.
- Imunon, Inc. amortization of debt issuance costs for the quarter ending 2013-03-31 was $31.56K.
| Period end | Amortization of Debt Issuance Costs 3 month | Amortization of Debt Issuance Costs 6 month | Amortization of Debt Issuance Costs 9 month |
|---|---|---|---|
| 2026-06-30 | $6.98K 10-Q · filed 2026-08-11 | ||
| 2013-09-30 | $35.70K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-12 | $67.26K derived: sum of 2 quarters · filed 2013-11-12 | $98.82K 10-Q · filed 2013-11-12 |
| 2013-06-30 | $31.56K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-08 | $63.12K 10-Q · filed 2013-08-08 | |
| 2013-03-31 | $31.56K 10-Q · filed 2014-08-07 | ||
| 2011-06-30 | $81.95K 10-Q · filed 2012-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |